Serum Immune-Response Protein Biomarkers Based on Olink Technology for Diagnosis of Ischemic Stroke

The immune response plays a crucial role in the treatment of ischemic stroke (IS). Our primary objective was to explore immune proteins related to stroke and to develop a noninvasive diagnostic panel. We used the high-throughput Olink immunoassay platform to quantitatively measure 92 proteins in the serum of 88 patients with IS and 88 controls. We first selected feature proteins using least absolute shrinkage and selection operator (LASSO), random forest (RF), and support vector machine (SVM), and then modeled them for external validation of IS. In this study, we found that 53 proteins exhibited significant differences in the IS compared to the control group. We selected GLB1, PRDX5, DDX58, and CLEC4C as potential protein biomarkers to differentiate IS from the control group using LASSO, RF, and SVM. The diagnostic model, which included these four proteins, demonstrated excellent performance in validation data sets, achieving an AUC value of 0.899 (95%CI: 0.848-0.950). Our findings offer valuable insights into both the immune response and the diagnosis of IS. These results offer a novel approach to clinical decision-making in the diagnosis and treatment of IS.